Fundraising Fox+ND Capital — 2021 Investments
4 investments dated 2021 · listed companies and verified rows first · show all
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)in
Co-investorsARCH Venture PartnersForbionVenrockFast Track InitiativeLifelinkNextech Invest+3 more
BiotechNew York, US
Masoud Tavazoie(Chief Scientific Officer)David Darst(Chief Operating Officer)Isabel Kurth(Vice President - Research)
BoardShahram Seyedin-Noor(Executive Chairman)Nancy Chang(Director)
Board seatPeter Van Vlasselaer· per SEC Form D · $11M raise · filed Feb 2021
Co-investorsOceanpine CapitalSofinnova Partners
Cytoki is a biotech company developing IL-22-based therapeutics using lipidation technology to treat metabolic diseases such as obesity and type 2 diabetes, as well as conditions involving epithelial injury like inflammatory bowel disease.
BiotechHealthtechVærløse, DK
Rasmus Jorgensen(CEO & Founder)in
Co-investorsYsios CapitalSeventure Partners
Lightcast provides a next-generation single-cell functional analysis platform called Envisia that enables massively parallel profiling of cell-cell interactions and biomolecule secretion at scale.
BiotechDeep TechMedical DevicesCambridge, GB
Co-investorsARCH Venture PartnersIllumina VenturesPerscitus LLPM VenturesOMX Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.